FOMOCAINE HYDROCHLORIDE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H25NO2.ClH
Molecular Weight	347.879
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.C(CN1CCOCC1)CC2=CC=C(COC3=CC=CC=C3)C=C2

InChI

InChIKey=HWDXMCUKRADNLV-UHFFFAOYSA-N

InChI=1S/C20H25NO2.ClH/c1-2-6-20(7-3-1)23-17-19-10-8-18(9-11-19)5-4-12-21-13-15-22-16-14-21;/h1-3,6-11H,4-5,12-17H2;1H

HIDE SMILES / InChI

Molecular Formula	C20H25NO2
Molecular Weight	311.418
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/international/fomocaine.html | https://www.ncbi.nlm.nih.gov/pubmed/20727863 | https://www.ncbi.nlm.nih.gov/pubmed/8786420 | https://www.ncbi.nlm.nih.gov/pubmed/114193 | https://www.ncbi.nlm.nih.gov/pubmed/6120706

Fomocaine is a local anesthetic used in the gel formulations for the relief of pain associated with burns and wounds. Fomocaine blocks both sodium and calcium voltage-gated ion cahnnel currents.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Voltage-dependent R-type calcium channel subunit alpha-1E 3 Target ID: CHEMBL1687682 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8786420	Blocker 555		100.0 µM [Ki]
Sodium channel alpha subunit 72 Target ID: CHEMBL2331043 Sources: https://www.ncbi.nlm.nih.gov/pubmed/20727863	Blocker 555

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 619 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1037079 https://www.ncbi.nlm.nih.gov/pubmed/1037080 https://www.ncbi.nlm.nih.gov/pubmed/114193 https://www.ncbi.nlm.nih.gov/pubmed/6120706	Primary		Approved 8583	Erbocain Approved Use Unknown Launch Date 1966

F_unbound

Value	Dose	Co-administered	Analyte	Population
5% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/581056/			FOMOCAINE plasma	Homo sapiens

PubMed

Title	Date	PubMed
Blockade of TTX-resistant and TTX-sensitive Na+ currents in cultured dorsal root ganglion neurons by fomocaine and the fomocaine derivative Oe 9000.	2010-10-28	20727863
A synopsis on different homologous series of fomocaine derivatives. In vitro interactions with the cytochrome P450 system, toxicity, and local anaesthetic effects in rats--Part III.	2007	18193689
A synopsis on different homologous series of fomocaine derivatives. In vitro interactions with the cytochrome P450 system, toxicity, and local anaesthetic effects in rats--part II.	2007	18074756
A synopsis on different homologous series of fomocaine derivatives. In vitro interactions with the cytochrome P450 system, toxicity, and local anaesthetic effects in rats--Part 1.	2007	17966754
[In vitro investigations of phase I metabolism of the fomocaine derivative Oe 9000 with pig liver homogenates].	2006-11	17152988
In vitro interactions with the Cytochrome P450 system, toxicity, and local anaesthetic effects of Fomocaine Alkylmorpholine derivatives in rats.	2006	16477999
Effects and toxicity of new fomocaine derivatives and of 2-hydroxypropyl-beta-cyclodextrin inclusion compounds in rats.	2004	15212188
Local anaesthetic effects and toxicity of seven new diethanolamine and morpholine derivatives of fomocaine. Testing in rats compared with procaine and tetracaine.	2003	12705179
[Synthesis and pharmacologic action of chiral fomocaine ((4-[2-methyl-3-(morpholin-4-yl)propyl)benzyl)-phenyl-ether and (4-(1-methyl-3-(morpholin-4-yl)propyl]benzyl)-phenyl-ether). 13. Synthesis of new compounds with local anesthetic action].	2001-08	11534337
[Physical chemical, pharmacological and toxicologic properties of fomocaine metabolites] .	2001-01	11215329
Local anaesthetic effectivity and toxicity of fomocaine, five N-free fomocaine metabolites and two chiralic fomocaine derivatives in rats compared with procaine.	2001	11455675

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Transdermal

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:10:08 GMT 2025` Edited by `admin` on `Mon Mar 31 22:10:08 GMT 2025`
Record UNII	96285SEX30
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

FOMOCAINE HYDROCHLORIDE

Common Name

English

MORPHOLINE, 4-(3-(4-(PHENOXYMETHYL)PHENYL)PROPYL)-, HYDROCHLORIDE

Preferred Name

English

MORPHOLINE, 4-(3-(4-(PHENOXYMETHYL)PHENYL)PROPYL)-, HYDROCHLORIDE (1:1)

Systematic Name

English

Fomocaine hydrochloride [WHO-DD]

Common Name

English

Code System Code Type Description

PUBCHEM

171527

Created by admin on Mon Mar 31 22:10:08 GMT 2025 , Edited by admin on Mon Mar 31 22:10:08 GMT 2025

PRIMARY

EPA CompTox

DTXSID80205137

Created by admin on Mon Mar 31 22:10:08 GMT 2025 , Edited by admin on Mon Mar 31 22:10:08 GMT 2025

PRIMARY

CAS

56583-43-8

Created by admin on Mon Mar 31 22:10:08 GMT 2025 , Edited by admin on Mon Mar 31 22:10:08 GMT 2025

PRIMARY

FDA UNII

96285SEX30

Created by admin on Mon Mar 31 22:10:08 GMT 2025 , Edited by admin on Mon Mar 31 22:10:08 GMT 2025

PRIMARY

Related Record Type Details


					4XO7A09HQM

FOMOCAINE

PARENT -> SALT/SOLVATE

Related Record Type Details


					4XO7A09HQM

FOMOCAINE

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: https://www.drugs.com/international/fomocaine.html | https://www.ncbi.nlm.nih.gov/pubmed/20727863 | https://www.ncbi.nlm.nih.gov/pubmed/8786420 | https://www.ncbi.nlm.nih.gov/pubmed/114193 | https://www.ncbi.nlm.nih.gov/pubmed/6120706

Originator

Approval Year

Targets

Conditions

Approved Use

Launch Date

Funbound

PubMed

Patents

Sample Use Guides

Description
Sources: https://www.drugs.com/international/fomocaine.html | https://www.ncbi.nlm.nih.gov/pubmed/20727863 | https://www.ncbi.nlm.nih.gov/pubmed/8786420 | https://www.ncbi.nlm.nih.gov/pubmed/114193 | https://www.ncbi.nlm.nih.gov/pubmed/6120706

F_unbound